My Cart

ENPP3

ENPP3 Overview

English NameEctonucleotide pyrophosphatase/phosphodiesterase family member 3Approved Drugs0
Drugs in Clinical Trials4Target SynonymEC:3.1.4.1,E-NPP 3,PD-Ibeta,NPPase,CD203c,PDNP3,Phosphodiesterase I/nucleotide pyrophosphatase 3,Nucleotide diphosphatase,ENPP3,DJ914N13.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),Phosphodiesterase-I Beta,Phosphodiesterase I Beta,CD203c Antigen,Gp130RB13-6,NPP3,B10,Ectonucleotide pyrophosphatase/phosphodiesterase family member 3,Ectonucleotide Pyrophosphatase/Phosphodiesterase 3,DJ1005H11.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),EC:3.6.1.9
Highest Development StagePhase 1 Clinical
English NameEctonucleotide pyrophosphatase/phosphodiesterase family member 3
Target SynonymEC:3.1.4.1,E-NPP 3,PD-Ibeta,NPPase,CD203c,PDNP3,Phosphodiesterase I/nucleotide pyrophosphatase 3,Nucleotide diphosphatase,ENPP3,DJ914N13.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),Phosphodiesterase-I Beta,Phosphodiesterase I Beta,CD203c Antigen,Gp130RB13-6,NPP3,B10,Ectonucleotide pyrophosphatase/phosphodiesterase family member 3,Ectonucleotide Pyrophosphatase/Phosphodiesterase 3,DJ1005H11.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),EC:3.6.1.9
Approved Drugs0
Drugs in Clinical Trials4
Highest Development StagePhase 1 Clinical

ENPP3 Background

The human NPP family contains seven members which can be classified into two groups according to their substrate preferences. The first class comprises the nucleotide-degrading proteins NPP1, 3 and 4. NPP3 (CD203c, ENPP3) is expressed in multiple organs, including on epithelial and mucosal surfaces, and notably on basophils and mast cells. Activation of basophils by antigen-bound IgE leads to release of inflammatory mediators and rapid upregulation of NPP3 to the cell surface. This protein is in fact a common marker for diagnosing allergen sensitivity with patient basophils by flow cytometry. Basophils and mast cells mediate the response to certain pathogens, as well as acute and chronic allergic reactions. Following activation, these cells release ATP, which further stimulates them in an autocrine manner. NPP3 upregulation serves to degrade ATP and suppress chronic allergic inflammation (but not the acute response).

ENPP3 Synonyms

ENPP3,CD203c,NPP3,E-NPP3,PD-Ibeta,NPPase,PDNP3

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
XmAb-819XmAb-819Phase 1 ClinicalXencor IncCarcinoma, Renal Cell; Kidney Neoplasms
Details
JNJ-89862175JNJ-89862175Phase 1 ClinicalJanssen Research & Development LlcSolid tumours
Details
ALY-301ALY-301; GTX-B001Phase 1 ClinicalAlys Pharmaceuticals IncChronic Urticaria; Symptomatic Dermographism; Urticaria
Details
JNJ-87890387JNJ-87890387Phase 1 ClinicalJanssen Research & Development LlcNeoplasms; Solid tumours
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland